Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DISEASE CHARACTERISTICS: \* Diagnosis of 1 of the following: * CLL or SLL, relapsed or refractory * Indolent B-cell lymphoma, relapsed or refractory: * Follicle center lymphoma, follicular or diffuse * Marginal zone B-cell lymphoma (splenic, nodal, extranodal \[this includes mucosa associated lymphoid tissue (MALT)\]) * Lymphoplasmacytic lymphoma * PTCL, relapsed or refractory: * Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive * Anaplastic large cell lymphoma, ALK-negative * Angioimmunoblastic T-cell lymphoma * Enteropathy-associated T-cell lymphoma * Extranodal natural killer (NK)/T-cell lymphoma, nasal type * Hepatosplenic T-cell lymphoma * PTCL, not otherwise specified (NOS) * Subcutaneous panniculitis-like T-cell lymphoma * CTCL: \* CTCL with subtypes of mycosis fungoides Stage IB or higher, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma who have failed a previous systemic treatment, as per the following: * Stage IA plaque, IB, or IIA: At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light \[PUVA\] and systemic corticosteroids) * Stage IIB, III, or IV: At least 1 prior systemic regimen (systemic corticosteroids alone or PUVA alone do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered 1 regimen * Prior allogeneic stem cell transplant is allowed provided that all of the following conditions are met: * \>= 6 months have elapsed since allogeneic transplant * No Graft vs. Host Disease (GVHD) is present * Not currently on immunosuppressive therapy * No prior or concurrent CNS malignancy PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * ANC \> 1,500/mm\^3 * Platelet count \> 75,000/mm\^3 * Hemoglobin \> 7.5 g/dL (transfusion allowed) * Serum creatinine ≤ 1.2 mg/dL or actual or calculated creatinine clearance \> 60 mL/min * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Bilirubin ≤ ULN * Serum potassium ≥ 3.5 mEq/L (supplementation allowed) * Serum magnesium ≥ 1.7 mEq/L (supplementation allowed) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective non-hormonal contraception * Willing and able to comply with protocol requirements * No prior severe allergic reactions to bortezomib, boron, mannitol, or romidepsin * No progressing toxicity secondary to bortezomib * No grade 1 peripheral neuropathy with pain or ≥ grade 2 peripheral neuropathy by NCI-CTCAE criteria (v4.0) within the past 14 days * No condition related to ischemic heart disease, heart failure, or the risk of torsades de pointes or sudden cardiac death, including any of the following: * History of sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes, or resuscitated cardiac arrest unless currently addressed with an implantable cardiac defibrillator * Baseline heart rate \> 140 beats per minute * Known congenital long QT syndrome * QTc interval \> 480 milliseconds * Type II second-degree atrio-ventricular (AV) block, third-degree AV block, or ventricular rate \< 50 beats per minute * Myocardial infarction within the past 6 months * Patients who have had a myocardial infarction 6-12 months ago are eligible provided they are asymptomatic and have a negative cardiac risk assessment (i.e., treadmill stress test, nuclear medicine stress test, or stress echocardiogram) * Angina upon ordinary physical activity * Angina only with strenuous, rapid, or prolonged exertion allowed * ECG with evidence of cardiac ischemia, as defined by the following: * ST depression of ≥ 2 mm, measured from isoelectric line to ST segment * T-wave inversion ≥ 4 mm, measured from isoelectric line to peak of T-wave * NYHA class II-IV congestive heart failure * Known left ventricular ejection fraction \< 40% by MUGA scan or \< 50% by echocardiogram or MRI * Known hypertrophic cardiomegaly or restrictive cardiomyopathy * No uncontrolled hypertension, defined as persistent blood pressure ≥ 160/95 mm Hg despite medical management * No clinically significant active infection, including known HIV infection or hepatitis B or C * No other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, in situ malignancy, or curatively treated low-risk prostate cancer * No concurrent medical condition that, in the investigator's opinion, would compromise study treatment or assessment of toxicity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 3 weeks since prior chemotherapy, radiation therapy or investigational agents. If steroids for cancer control have been used, patients must be off theses agents for at least 1 week before starting treatment. (Maintenance therapy for non-malignant disease with prednisone or steroid equivalent dose less than 10 mg/day is permitted) * Prior allogeneic stem cell transplantation allowed provided all of the following conditions are met: * Greater than or equal to 6 months have elapsed since allogeneic transplant * No Graft vs. Host Disease (GVHD) is present * More than 4 weeks since prior bortezomib * No concurrent oral hormonal contraceptives * No concurrent potent or moderate CYP3A4 inhibitors * No concurrent anti-arrhythmic agents * No concurrent treatment with any drugs that are generally accepted to having a risk of causing torsades de pointes (class 1 drugs) * Class 2 or 3 drugs allowed at the discretion of the investigator * No other concurrent systemic therapy for the malignancy * Concurrent warfarin (coumadin) allowed